<table border="0" cellpadding="0" cellspacing="0" width="border-collapse: collapse" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Digoxin </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">During concomitant use of naproxen and digoxin, monitor serum digoxin levels. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Lithium </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance<content stylecode="italics">. </content>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">During concomitant use of naproxen and lithium, monitor patients for signs of lithium toxicity. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Methotrexate </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">During concomitant use of naproxen and methotrexate, monitor patients for methotrexate toxicity. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Cyclosporine </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Concomitant use of naproxen and cyclosporine may increase cyclosporineâ€™s nephrotoxicity. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">During concomitant use of naproxen and cyclosporine, monitor patients for signs of worsening renal function. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">NSAIDs and Salicylates </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Concomitant use of naproxen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content stylecode="italics">(see <linkhtml href="#Section_5.2">WARNINGS; Gastrointestinal Bleeding, Ulceration and Perforation</linkhtml>). </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of naproxen with other NSAIDs or salicylates is not recommended. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Pemetrexed </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Concomitant use of naproxen and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). <br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention: </content>
<br/>
</td>
<td stylecode="Rrule" valign="top">During concomitant use of naproxen and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.<br/>
</td>
</tr>
</tbody>
</table>